LCTX Clinical trials

Lineage Announces Dosing of First Patient in New Clinical Study of OPC1 for Subacute and Chronic Spinal Cord Injury

Published August 04, 2025 at 12:00 PM

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious neurological and ophthalmic conditions, announced today that the first-ever chronic spinal cord injury patient has been treated in the Company’s DOSED (Delivery of Oligodendrocyte Progenitor Cells (OPCs) for Spinal Cord Injury: Evaluation of a Novel Device) clinical study at UC San Di

Related Questions

What are the potential regulatory pathways and requirements for the OPC1 therapy, and how could they affect future cash burn and financing needs? When is the next patient enrollment milestone and when can we expect interim data readouts from the DOSED study? What are the anticipated enrollment targets for subacute versus chronic spinal cord injury cohorts, and how might deviations impact the valuation? Will the outcomes of this initial dosing influence the company’s ability to secure additional strategic partnerships or licensing deals? How might the news of first patient dosing impact the short‑term trading volume and price volatility of LCTX? How does Lineage's OPC1 program compare to competing cell therapy approaches for spinal cord injury in terms of efficacy, safety, and commercialization timeline? Are there any disclosed adverse events or safety signals from this first patient that could raise concerns among investors? How does the dosing of the first chronic spinal cord injury patient affect the projected timeline for potential FDA approval or breakthrough therapy designation? What is the estimated market size for subacute and chronic spinal cord injury treatments, and what share can Lineage realistically capture if trials are successful? What are the company’s projected costs for advancing the DOSED trial through Phase 2/3, and how will this affect runway and potential dilution?